What is BIXT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BIXT?

P/E (TTM) is n/a and 52-week range is $0.02 to $0.09 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BIXT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BIXT?

The company profile lists revenue (TTM) near $140K, net income (TTM) near $-21M, EPS (TTM) near $-0.03 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bioxytran Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Needham, Massachusetts, US, 114.2M shares outstanding, ISIN US09075D1028 when available from company profile and filing metadata.

Bioxytran Inc

$BIXT

Health Care · Biotechnology

IR Run Scenarios

$0.02

-2.55%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The firm is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The firm's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Website

www.bioxytraninc.com/

IPO

2010-01-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)